Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration

ACS Chemical Biology

Volumn 6, Issue 6, 2011, Pages 658-666

  Kaoud, Tamer S ^a   Mitra, Shreya ^b   Lee, Sunbae ^a   Taliaferro, Juliana ^a,c   Cantrell, Michael ^d   Linse, Klaus D ^e   Van Den Berg, Carla L ^d   Dalby, Kevin N ^a  

^a Division of Medicinal Chemistry   (United States)

^b Division of Pharmacology and Toxicology   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d XBiotech USA Inc   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANISOMYCIN; ARGININE; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE P38; PROLYLLYSYLARGINYLPROLYLTHREONYLTHREONYLLEUCYLASPARAGINYLLEUCYLPHENYLALANYLAMINOHEXANOYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGININE; PROLYLLYSYLARGINYLPROLYLTHREONYLTHREONYLLEUCYLASPARAGINYLLEUCYLPHENYLALANYLAMINOHEXANOYLARGINYLARGINYLARGINYLGLUTAMINYLARGINYLARGINYLLYSYLLYSYLARGINYLGLYCINE; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; BREAST CANCER; CANCER CELL CULTURE; CELL MIGRATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 9; NEOPLASM METASTASIS; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 79958100824     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb200017n     Document Type: Conference Paper

References (35)

1. Davis, R. J. (2000) Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252.
2. Manning, A. M., and Davis, R. J. (2003) Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discovery 2, 554-565. (Pubitemid 37361747)
3. Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Derijard, B., and Davis, R. J. (1996) Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15, 2760-2770. (Pubitemid 26176253)
4. Bogoyevitch, M. A., Ngoei, K. R., Zhao, T. T., Yeap, Y. Y., and Ng, D. C. (1804) c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim. Biophys. Acta 463-475.
5. Kennedy, N. J., and Davis, R. J. (2003) Role of JNK in tumor development. Cell Cycle 2, 199-201.
6. Shibata, W., Maeda, S., Hikiba, Y., Yanai, A., Sakamoto, K., Nakagawa, H., Ogura, K., Karin, M., and Omata, M. (2008) c-Jun NH2- terminal kinase 1 is a critical regulator for the development of gastric cancer in mice. Cancer Res. 68, 5031-5039.
7. Bogoyevitch, M. A., and Kobe, B. (2006) Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol. Mol. Biol. Rev. 70, 1061-1095. (Pubitemid 44958264)
8. Igaki, T., Pagliarini, R. A., and Xu, T. (2006) Loss of cell polarity drives tumor growth and invasion through JNK activation in Drosophila. Curr. Biol. 16, 1139-1146. (Pubitemid 43815753)
9. Potapova, O., Anisimov, S. V., Gorospe, M., Dougherty, R. H., Gaarde, W. A., Boheler, K. R., and Holbrook, N. J. (2002) Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res. 62, 3257-3263. (Pubitemid 34602422)
10. Antonyak, M. A., Kenyon, L. C., Godwin, A. K., James, D. C., Emlet, D. R., Okamoto, I., Tnani, M., Holgado-Madruga, M., Moscatello, D. K., and Wong, A. J. (2002) Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21, 5038-5046.
11. Tsuiki, H., Tnani, M., Okamoto, I., Kenyon, L. C., Emlet, D. R., Holgado-Madruga, M., Lanham, I. S., Joynes, C. J., Vo, K. T., and Wong, A. J. (2003) Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res. 63, 250-255. (Pubitemid 36070447)
12. Chen, N., Nomura, M., She, Q. B., Ma, W. Y., Bode, A. M., Wang, L., Flavell, R. A., and Dong, Z. (2001) Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res. 61, 3908-3912. (Pubitemid 32720949)
13. Chen, P., O'Neal, J. F., Ebelt, N. D., Cantrell, M. A., Mitra, S., Nasrazadani, A., Vandenbroek, T. L., Heasley, L. E., and Van Den Berg, C. L. (2010) Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model. PLoS One 5, e10443.
14. Mitra, S., Lee, J. S., Cantrell, M., and Van Den Berg, C. L. (2011) cJun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J. Biol. Chem.in press.
15. Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., and Horwitz, A. R. (2003) Cell migration: integrating signals from front to back. Science 302, 1704-1709. (Pubitemid 37505725)
16. Huang, C., Jacobson, K., and Schaller, M. D. (2004) MAP kinases and cell migration. J. Cell Sci. 117, 4619-4628. (Pubitemid 39433429)
17. Weston, C. R., and Davis, R. J. (2007) The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19, 142-149. (Pubitemid 46386399)
18. Chen, T., Kablaoui, N., Little, J., Timofeevski, S., Tschantz, W. R., Chen, P., Feng, J., Charlton, M., Stanton, R., and Bauer, P. (2009) Identification of small-molecule inhibitors of the JIP-JNK interaction. Biochem. J. 420, 283-294.
19. Stebbins, J. L., De, S. K., Machleidt, T., Becattini, B., Vazquez, J., Kuntzen, C., Chen, L. H., Cellitti, J. F., Riel-Mehan, M., Emdadi, A., Solinas, G., Karin, M., and Pellecchia, M. (2008) Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc. Natl. Acad. Sci. U.S.A. 105, 16809-16813.
20. Whitmarsh, A. J., Kuan, C. Y., Kennedy, N. J., Kelkar, N., Haydar, T. F., Mordes, J. P., Appel, M., Rossini, A. A., Jones, S. N., Flavell, R. A., Rakic, P., and Davis, R. J. (2001) Requirement of the JIP1 scaffold protein for stress-induced JNK activation. Genes Dev. 15, 2421-2432. (Pubitemid 32899745)
21. Heo, Y. S., Kim, S. K., Seo, C. I., Kim, Y. K., Sung, B. J., Lee, H. S., Lee, J. I., Park, S. Y., Kim, J. H., Hwang, K. Y., Hyun, Y. L., Jeon, Y. H., Ro, S., Cho, J. M., Lee, T. G., and Yang, C. H. (2004) Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J. 23, 2185-2195.
22. Kaneto,H.,Nakatani, Y., Miyatsuka, T., Kawamori,D.,Matsuoka, T. A., Matsuhisa, M., Kajimoto, Y., Ichijo, H., Yamasaki, Y., and Hori, M. (2004) Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat. Med. 10, 1128-1132. (Pubitemid 39424876)
23. Barr, R. K., Kendrick, T. S., and Bogoyevitch, M. A. (2002) Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem. 277, 10987-10997. (Pubitemid 34952855)
24. Barr, R. K., Boehm, I., Attwood, P. V., Watt, P. M., and Bogoyevitch, M. A. (2004) The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J. Biol. Chem. 279, 36327-36338. (Pubitemid 39128970)
25. Yan, C., Kaoud, T. S., Lee, S., Dalby, K. N., and Ren, P. (2010) Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1. J. Phys. Chem. B 115, 1491-1502.
26. Ekokoski, E., Aitio, O., Tornquist, K., Yli-Kauhaluoma, J., and Tuominen, R. K. (2010) HIV-1 Tat-peptide inhibits protein kinase C
27. Guan, Q. H., Pei, D. S., Zong, Y. Y., Xu, T. L., and Zhang, G. Y. (2006) Neuroprotection against ischemic brain injury by a small peptide inhibitor of c-Jun N-terminal kinase (JNK) via nuclear and non-nuclear pathways. Neuroscience 139, 609-627.
28. Bonny, C., Oberson, A., Negri, S., Sauser, C., and Schorderet, (Pubitemid 32047984)
29. Borsello, T., Clarke, P. G., Hirt, L., Vercelli, A., Repici, M., Schorderet, D. F., Bogousslavsky, J., and Bonny, C. (2003) A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9, 1180-1186. (Pubitemid 37173703)
30. Kuan, C. Y., and Burke, R. E. (2005) Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr. Drug Targets CNS Neurol. Disord. 4, 63-67. (Pubitemid 41403315)
31. Repici, M., Mare, L., Colombo, A., Ploia, C., Sclip, A., Bonny, C., Nicod, P., Salmona, M., and Borsello, T. (2009) c-Jun N-terminal kinase binding domain-dependent phosphorylation of mitogen-activated protein ACS Chemical Biology ARTICLES kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing cross-talk between c-JunN-terminal kinase and extracellular signal-regulated kinase pathways in cortical neurons. Neuroscience 159, 94-103.
32. Renlund, N., Pieretti-Vanmarcke, R., O'Neill, F. H., Zhang, L., Donahoe, P. K., and Teixeira, J. (2008) c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptormediated signal transduction. Endocrinology 149, 108-115.
33. Madsen, J. A., Kaoud, T. S., Dalby, K. N., and Brodbelt, J. S.
34. Szafranska, A. E., Luo, X., and Dalby, K. N. (2005) Following in vitro activation of mitogen-activated protein kinases by mass spectrometry and tryptic peptide analysis: purifying fully activated p38 mitogenactivated protein kinase alpha. Anal. Biochem. 336, 1-10. (Pubitemid 39593493)
35. Morrison, J. F. (1969) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 185, 269-286.